News | PET Imaging | October 25, 2022

The oral presentation includes additional results from Blue Earth's Phase 3 SPOTLIGHT study evaluating the impact of clinical factors on the detection rate of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy

The oral presentation includes additional results from Blue Earth's Phase 3 SPOTLIGHT study evaluating the impact of clinical factors on the detection rate of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy

October 25, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced presentations on Axumin (fluciclovine F 18) and investigational 18F-rhPSMA-7.3 at the upcoming American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting, to be held in San Antonio, Texas, from October 23 to 26, 2022. Details of selected oral and moderated poster presentations are listed below. 

An oral presentation on the investigational radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) compound, 18F-rhPSMA-7.3, is being made at the conference. It includes additional results from the Company’s Phase 3 SPOTLIGHT study (NCT04186845) evaluating the impact of clinical factors on the detection rate of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy. Presentations on studies of Axumin (fluciclovine F 18) include interim analyses from a randomized trial of 18F-fluciclovine and 68Ga-PSMA PET/CT in post-prostatectomy radiotherapy, experience on the prognostic utility of 18F-fluciclovine PET after salvage radiotherapy, and timing and patterns of potentially salvageable recurrences after SBRT for localized prostate cancer. Additionally, the Company will host an Industry-Expert Theater event, “Emerging Data on the Impact of Axumin® (fluciclovine F 18) PET Imaging on Radiotherapy Decisions.” Details of selected oral and poster presentations by Blue Earth Diagnostics and its collaborators are listed below. 

NOTE: Axumin (fluciclovine F 18) injection is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate-specific antigen (PSA) levels following prior treatment. Currently, 18F-rhPSMA-7.3 is investigational and has not received regulatory approval. 

   

  

HIGHLIGHTED SCIENTIFIC PRESENTATIONS 

Monday, October 24, 2022 

   

  

Investigational 18F-rhPSMA-7.3 presentation 

Category: 

 

Genitourinary Cancer 

Title: 

 

1049 Impact of Clinical Factors on 18F-rhPSMA-7.3 Detection Rates in Men with Recurrent Prostate Cancer: Findings from the Phase 3 SPOTLIGHT Study 

Presenter: 

 

Benjamin Lowentritt, MD, Chesapeake Urology Associates, Towson, Md. 

Session Type 

 

Quick Pitch 

Session Title: 

 

QP 09 – GU 3 – Salvage, SABR and Protons for Prostate Cancer 

Presentation Time: 

 

5:05 PM CT 

Location: 

 

Henry B. Gonzalez Convention Center, Room 304 

Presentation No.: 

 

1049 

   

  

   

  

Tuesday, October 25, 2022 

   

  

Axumin (fluciclovine F 18) presentations 

Category: 

 

Genitourinary Cancer 

Title: 

 

Prognostic Utility of (18)F-Fluciclovine Positron Emission Tomography (FACBC) in Biochemically Recurrent (BCR) Prostate Cancer (PCa) Treated with Salvage Radiotherapy 

Presenter: 

 

Graham Campbell, MD, University of Wisconsin Hospital and Clinics, Madison, Wis. 

Session Title: 

 

PQ 06 – Poster Q&A 06 – Session 06 – Genitourinary Cancer, Patient Safety and Nursing 

Presentation Time: 

 

2:30 PM CT 

Location: 

 

Henry B. Gonzalez Convention Center, Exhibit Hall 1 

Presentation No.: 

 

2478 

   

  

Category: 

 

Genitourinary Cancer 

Title: 

 

Timing and Patterns of Potentially Salvageable Recurrences Following SBRT for Clinically Localized Prostate Cancer Assessed by Preferential Amino Acid Uptake 

Presenter: 

 

Michael Carrasquilla, MD, Department of Radiation Medicine, Medstar Georgetown University Hospital, Washington, DC 

Session Title: 

 

Poster Q&A 06 – Session 06 – Genitourinary Cancer, Patient Safety and Nursing 

Presentation Time: 

 

2:30 PM CT 

Location: 

 

Henry B. Gonzalez Convention Center, Exhibit Hall 1 

Presentation No.: 

 

2479 

   

  

Category: 

 

Genitourinary Cancer 

Title: 

 

Randomized Trial of 18F-fluciclovine vs 68Ga-PSMA PET/CT Guided Post-Prostatectomy Radiotherapy: Interim Volumetric and Patient-Reported Toxicity Analyses 

Presenter: 

 

Vishal Ramesh Dhere, MD, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga. 

Session Title: 

 

Poster Q&A 06 – Session 06 – Genitourinary Cancer, Patient Safety and Nursing 

Presentation Time: 

 

2:30 PM CT 

Location: 

 

Henry B. Gonzalez Convention Center, Exhibit Hall 1 

Presentation No.: 

 

2489 

   

  

Blue Earth Diagnostics invites participants at the 2022 ASTRO Annual Meeting to attend the presentations above and visit the company at Exhibit Booth 4142. Blue Earth Diagnostics is hosting an Industry-Expert Theater event, “Emerging Data on the Impact of Axumin (fluciclovine F 18) PET Imaging on Radiotherapy Decisions,” with invited speaker Dr. Edward Obedian, MD, Radiation Oncologist, St. Francis Hospital, Long Island, NY. The event will be held on Sunday, October 23, 2022, from 11:00 AM to 12:00 PM CT, in Room 216, Meeting Level, Henry B. Gonzalez Convention Center. For full session details and scientific presentation listings, please see the ASTRO online program here

Indication and Important Safety Information About Axumin 

INDICATION 

Axumin (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. 

IMPORTANT SAFETY INFORMATION 

Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended. 

Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available. 

Axumin use contributes to a patient’s overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers. 

Adverse reactions were reported in ≤ 1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia. 

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Full Axumin prescribing information is available at https://www.axumin.com/prescribing-information.pdf

Find more ASTRO22 content here 


Related Content

News | Radiation Oncology

November 28, 2022 — Dunlee unveiled its new oncology bundles in the U.S. for the first time at Radiological Society of ...

Time November 28, 2022
arrow
News | RSNA | By Christine Book

November 27, 2022 — Among dozens of technical exhibit visits, informative discussions, and captivating Plenary Session ...

Time November 27, 2022
arrow
News | RSNA

November 21, 2022 — Taking anti-inflammatory pain relievers like ibuprofen and naproxen for osteoarthritis may worsen ...

Time November 21, 2022
arrow
Videos | ASTRO

Dr. Frank A. Vicini, MD, FACR, FASTRO, FABS, who is a radiation oncologist with GenesisCare, discussed his findings from ...

Time November 09, 2022
arrow
News | Radiation Therapy

November 8, 2022 — Elekta announced that Elekta Esprit, a new Leksell Gamma Knife radiosurgery platform, received FDA ...

Time November 08, 2022
arrow
News | Artificial Intelligence

Nov. 4, 2022 — Guerbet announced an agreement with Merative formalizing the termination of their collaboration initiated ...

Time November 05, 2022
arrow
News | Artificial Intelligence

Nov. 4, 2022 — The U.S. Food and Drug Administration (FDA) is recommending health care providers discuss alternative ...

Time November 05, 2022
arrow
News | Proton Therapy

November 3, 2022 — Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation ...

Time November 03, 2022
arrow
Feature | Lung Imaging | By Christine Book

The pace of new lung cancer screening initiatives, published research and collective efforts of organizations and ...

Time November 03, 2022
arrow
News | Radiation Therapy

November 2, 2022 — ViewRay, Inc. announced the launch of a phase III randomized controlled trial titled "Locally ...

Time November 02, 2022
arrow
Subscribe Now